Skip to content

Assessing Health System Readiness for Scaling Antenatal MMS in Cambodia

Assessing Health System Readiness for Scaling Antenatal MMS in Cambodia: A Mixed-Methods Assessment

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07400796
Acronym
TIPS-Cambodia
Enrollment
710
Registered
2026-02-10
Start date
2025-12-01
Completion date
2026-06-30
Last updated
2026-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adherence, Anemia, Health Systems, Micronutrients, Pregnancy, Supplement, Supply Chain Vulnerabilities

Keywords

anemia, nutrition, micronutrient, supplement, dietary supplement, Cambodia, policy

Brief summary

Malnutrition among pregnant women in low- and middle-income countries (LMICs) can cause micronutrient deficiencies that result in adverse maternal and neonatal health outcomes. The World Health Organization has recently recommended antenatal multiple micronutrient supplementation (MMS) that includes iron and folic acid (IFA) to improve maternal and neonatal health outcomes. MMS likely provides additional antenatal benefits over IFA supplementation alone. The Cambodian government, in partnership with Helen Keller International, is piloting MMS implementation in Takeo Province, which will inform nationwide scale-up of MMS. Study Purpose: The Takeo implementation must be evaluated to understand context-specific implementation of MMS and health system readiness for scale-up. This study assesses system readiness through four domains from the Intervention Scalability Assessment Tool (ISAT): (1) fidelity and adaptation, (2) reach and acceptability, (3) delivery setting and workforce capacity, and (4) implementation infrastructure. Population: The pilot involves transitioning to MMS from IFA across all 86 health centers, all 6 referral hospitals, and the provincial hospital in Takeo province. This study includes pregnant women receiving antenatal care, antenatal healthcare providers and facilities, and hospital managers in Takeo. The study also includes national governing bodies for MMS delivery. Methods: This mixed-methods study uses ISAT as a framework for developing data collection methods. Sampling strategies emphasize urban and rural representation across all operational districts in Takeo and diverse stakeholder perspectives at multiple levels of the health system. Data collection includes: * 12 focus group discussions (FGDs) with health center providers to assess provider adherence to MMS delivery guidelines, perspectives on the transition to MMS, and additional resources needed for MMS delivery * Workload assessment surveys at FGDs to quantify any burden on providers and resource gaps to deliver MMS * MMS stockout monitoring at 18 health centers and 7 hospitals to assess supply chain reliability * 15 key informant interviews with hospital managers to assess perspectives on the integration of MMS into antenatal services and facility readiness for MMS delivery * Phone surveys with 630 pregnant women to assess acceptability and adherence to MMS at 90- and 180-days after MMS distribution * One FGD with national-level stakeholders to assess national-level readiness, economic planning, and resource planning for sustainable MMS implementation and scale-up * Rapid economic evaluation to estimate the cost of nationwide scale-up Potential Impact: This study will generate insights into real-world implementation of MMS in Cambodia. It will identify context-specific adaptations, implementation gaps, and resource planning frameworks needed for nationwide scale-up of MMS. Successful scale-up is anticipated to improve maternal and neonatal health in Cambodia. Findings can also be used to guide other LMICs seeking to transition to and sustainably implement MMS.

Interventions

DIETARY_SUPPLEMENTMultiple micronutrient supplement (MMS) for pregnancy

Standard of care MMS during pregnancy (180 tablets total)

Sponsors

University of British Columbia
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

For the cohort of pregnant individuals consuming MMS: Inclusion Criteria: * Current pregnant * At least 18 years of age * Have attended at least one ANC visit at a health center or hospital in Takeo during the study period * Can provide a functioning phone number for follow-up contact * Willingness to participate and provide consent

Exclusion criteria

* Individuals with diagnosed anemia who require iron and folic acid (IFA) supplementation instead of MMS * Individuals unable to communicate via telephone,;(3) individuals who withdraw consent at any point

Design outcomes

Primary

MeasureTime frameDescription
Perspectives on the transition to MMS4 months12 FGD with health care providers

Secondary

MeasureTime frameDescription
National-level readiness, economic planning, and resource planning for sustainable MMS implementation and scale-up4 monthsFGD with national-level stakeholders
Perspectives on the integration of MMS into antenatal services and facility readiness for MMS delivery4 monthsFGD with hospital managers (key informant interviews)
Provider adherence to MMS delivery guidelines4 months12 FGD with health care providers
Adherence of pregnant individuals to MMS supplementation6 monthsAdherence, %, of the total 180 tablets prescribed
Quantification of any burden on providers and resource gaps to deliver MMS4 monthsWorkload assessment surveys among the 15 FGD with health center providers
Additional resources needed for successful MMS delivery4 months12 FGD with health care providers

Countries

Cambodia

Contacts

CONTACTMeng Sokchea Program Manager, Helen Keller International, MD
MSokchea@hki.org+855 023 213 217
CONTACTVannary Hun, MPH
vhun@hki.org+855 12 612 912
STUDY_DIRECTORHou Kroeun, MPH

Helen Keller International

PRINCIPAL_INVESTIGATORCrystal Karakochuk, PHD

University of British Columbia

STUDY_DIRECTORMai Hoang, MPH

Helen Keller International

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026